Seattle Biotech NanoString's Revenue Up 20% as Company Shifts Focus to Cancer Diagnostics

Published: Aug 05, 2015

Seattle biotech NanoString (Nasdaq: NSTG) on Tuesday posted a $12.4 million loss — a loss of 66 cents per share — on a revenue of $13.1 million for the second quarter.

Revenue grew 20 percent compared to the same period last year, when the company posted a $10.9 million revenue. Losses were down year-over-year, from $14 million in the second quarter of 2014.

NanoString develops diagnostic tools to help researchers and drug companies understand what goes wrong in a person's DNA that causes a cancer to develop, and how well treatments work for each individual.

Help employers find you! Check out all the jobs and post your resume.

Back to news